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Herpes simplex virus (HSV) is one of the most common infectious agents of
man . One important featureof this virus is its ability toproducealatent infection .
The reactivation of this infection, however, generally does not result ina viremia
but rather spreads between cells. Thus, even though an antibody response is
induced, it mightbe expected that a cellular mechanism of protection is required
(1) . Clinical data supports the notion that high anti-HSV virus-neutralizing
antibody (VNA)' titers do not protect from reinfection and reactivation in man
(2, 3), and may in fact play a negative role in protection from HSV (4, 5) .
In considering mechanisms of protection other than antibody, we have been
studying the T cell response in mice to glycoprotein D (gD), a viral encoded
molecule found on the surface of infected cells . We found that immunization
with a 23-amino-acid synthetic peptide having a sequence corresponding to the
NH3-terminus of gD from either HSV-1 or HSV-2 induces a T cell response in
vitro against related peptides (6) and HSV itself. This peptide will also induce
antibody that can neutralize viral infectivity (7, 8) . We were, of course, interested
in determining the ability of these peptides to protect against an HSV challenge
in vivo . In an attempt to construct an antigen capable of enhancing the T cell
response (9, 10), we coupled the peptides to palmitic acid side chains (11) and
inserted these acylated peptides into a liposome structure (12) . This report
describes the protection achieved and its ability to be transferred by T cells and
not serum .
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Materials and Methods
Antigen Preparation .
￿
Peptides were synthesized and purified as previously described
(6) . To add the palmitic acid side chains onto these peptides, a tripeptide linker, GGK,
was added to the NH3 terminus ; the NH 3-terminal lysine was coupled as the bis-t-
butyloxycarbonyl derivative, and deprotected using trifluoroacetic acid .The palmitic acid
moieties were coupled by the symmetric anhydride methods (11). This molecule was then
mixed with lipids as follows (12) . Phosphatyl choline, cholesterol, and lysolecithin were
each dissolved in methanol/chloroform (1 :3) and then mixed in the ratio of 16:2:1,
respectively .
This work was supported by the R. J . Reynolds Company, by U .S. Public Health Service Grants AI-
22528 and NS-11036, andby grant IM-417 from the American Cancer Society .
' Abbreviations used in this paper:
￿
BHK, baby hamster kidney ; EAE, experimental allergic enceph-
alomyelitis ; gD, glycoprotein D; VNA, virus-neutralizing antibody .
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Palmitic acid
￿
K-D-GI-'X-Y-A-L-A-D-P-S-L-K-M-A-D-P-N-R-F-R-D-K-N-L-P
21
I
FIGURE 1 . The first 23 NH3-terminal amino acids of the gD of HSV-2 are shown attached
to a spacer, Gly-Gly-Lys, and then covalently coupled to two palmitic acid molecules.
This mixture was then dried with a nitrogen stream, rotating the vial in warm water to
get an even film over the entire vial . 5 mg of the peptide-palmitic acid conjugate was
dissolved in 2 ml of a 1 % octylglycoside in PBS and then added to 10 mg of the lipid
mixture . The mixture was dialyzed against PBS using a 3.5-kD cutoff Spectropore dialysis
membrane for 24 h . The liposomes were probe-sonicated for 5 min . The peptide-
containing liposome preparation (see Fig. 1 for diagram of this molecular structure) was
then mixed withCFA in a ratio of 1 :1 into an emulsion and injected into the hind footpads
of mice . The volume given was ^-0.2 ml/ animal, and the amount of peptide was 150
,ug/animal or 10,ug/gm body weight .
The HSV-1 and HSV-2 NH3-terminal 1-23 sequences differ at two residues : at residue
7, where the HSV-1 sequence is Ala and the HSV-2 sequence is Pro, and at residue 21,
where the HSV-1 sequence is Asp and the HSV-2 sequence is Asn (13) . As demonstrated
in Fig . 2A, '4C-labeled acylated 1-23(1)-peptide liposomes with the gD sequence ofHSV-
1 are homogeneous in regard to their buoyant density ; moreover, the buoyant density of
these peptide-liposomes correlate with the amount of peptide incorporated . Such purified
liposomes were examined by electronmicroscopy (Fig . 2, B and C) and found to be an
average of 250 nm in diameter, and multilammelar. The membrane of the peptide-
liposomes exhibited a higher electron density compared with the lipid membranes, which
do not contain peptide . This may indicate that the peptide is incorporated, at least in
part, into the lipid membrane .
Virus Preparation and Challenge .
￿
HSV-1 strain F was obtained from Nigel Fraser
(Wistar Institute), and HSV-2 strain 186 was obtained from Gary Cohen (University of
Pennsylvania School of Dental Medicine, Philadelphia, PA) . Both viruses were grown in
baby hamster kidney (BHK) fibroblast cells . Infected cells (10') were resuspended in 1 ml
ofmedium, frozen and thawed three times, and virus titer was determined by counting
PFU on BHK monolayers . Challenge with infectious virus was carried out by injection of
both footpads with a given dose ofHSV-2 in culture supernatant .
Virus Neutralization .
￿
In 96-well flat bottom tissue culture plates, 100 PFU of virus in
25 jul was added to serum antibody, in the same volume, with the serum being diluted in
twofold dilutions . This mixture was incubated for 1 h at 37'C, and BHK cells were added
to the wells at a concentration of 5 X 104 cells/ml in 50 ul . 3-4 d later, the cells were
stained with crystal violet dissolved in 10% phosphate buffered formalin . The titer is
reciprocal dilution of the geometric mean of the number of wells of a twofold dilution .
T Cell Preparation and Responses .
￿
Cell suspensions obtained from the popliteal and
inguinal lymph nodes of animals immunized with antigen 2 wk previously were passed
over a nylon wool column (14), the T cells were purified, and then cultured with x-
irradiated spleen (2,500 rad) plus antigen . These cultures were tested for responsiveness
to antigen by cell proliferation measured by the incorporation of ['H]thymidine after 3 d
in culture (15) .WATARI ET AL .
￿
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FIGURE 2 .
￿
(A) "C-Labeled palmitic acid-peptide-liposomes were layered on a continuous
5-15% sucrose gradient and centrifuged to 35,000 rpm in a Beckmann SW 50.1 rotor at
10 ° C . Fractions were collected and counted for radioactivity and density was determined for
the peak fractions : (open circles), a density of 1 .020, with a peptide/lipid ratio of 4:10 ; (filled
circles), a density of 1.017, with a ratio of 3:10 ; (open triangles), a density of 1 .014, with a ratio
of2:10 ; and (felled triangles), a density of 1 .010, with a ratio of 1 :10 . Electronmicrographs of
liposomes (B) or peptide-liposomes at a peptide/lipid ratio of 4:10 (C) .
For adoptive transfer experiments, cell suspensions from spleen and lymph nodes were
treated with both 14 .4 .4, an anti-I-Ea monoclonal antibody (16), andJ 11 D, an anti-B cell
monoclonal antibody (17), and in some cases 3 .168, an anti-Lyt-2 antibody (18), plus C'
for 75 min at 37°C . These cells were then tested for their response to LPS and Con A in
the presence of x-irradiated normal splenocytes .
Results
BALB/c female mice at 6 wk of age were given a single dose of the acylated
1-23(2) peptide liposome with the NH3-terminal sequence of gD from HSV-2
and then tested for protection by challenging with a lethal dose of HSV-2, after
intervals of up to 7 mo .
It is clear from Fig . 3 that HSV-2 infection leads to pathogenic effects (a
characteristic paralysis) in unprotected mice by day 8, that death ensues -6-10
d later, and that a single dose of acylated peptide-liposome is protective . We
have shown both the percentage of mice without symptoms and the percentage462 PEPTIDE-SPECIFIC T CELLS PROTECT FROM HERPES SIMPLEX VIRUS
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FIGURE 3.
￿
BALB/c female mice at 6 wk ofage were immunized with a single dose ofantigen
and then challenged with lethal dose of HSV-2 . The data is presented as both the percentage
of mice without symptoms (A, B, C) and the percentage of mice surviving (A', B', C') versus
the number of days after HSV-2 challenge . Symptoms include : ruffled fur, shaking, paralysis,
and death . The antigens used for immunization include : UV-inactivated HSV-1 in CFA (O);
acylated peptide-liposome in CFA hg (A) ; CFA alone (0) ; acylated peptide-liposome in saline
(*); liposome in CFA (O) ; acylated peptide in CFA (/); and saline (") . (A and A') Mice were
immunized once, 2 .5 mo before challenge, and received 1.2 x 10 6 PFU of challenge virus . (B
and B') Mice were immunized 2.5 mo before challenge with 2.2 X 106 PFU of HSV-2 . (C and
C') Mice were immunized once, 7 mo before challenge with 3 .1 X 10 6 PFU of virus.
/H
of mice surviving up to 120 d after virus challenge, which essentially describes
the time of onset and the endpoint of HSV disease in these mice . Fig . 3,A and
A' (Exp . 1) illustrate the results when animals were challenged with a 1 .2 X 106
PFU dose of HSV-2 (4-LD50), 2 .5 mo after immunization . If the mice were
immunized with either UV-inactivated HSV-1 (10 mice) or acylated peptide-
liposome (14 mice) in CFA, 100% of them were protected . When the controls
were immunized with either saline (10 mice), or liposome (in the absence of
peptide) in CFA (11 mice), 30-45% of the animals survived the challenge
infection .
Interestingly, a fifth experimental group receiving the acylated peptide-
liposome in saline (5 mice) did far worse than the controls. This result, notjust
a lack of protection but rather an enhanced frequency of disease, points to the
importance of considering the different forms of immunogen and their effects,
both positive and negative .
To better determine the effectiveness of antigen priming, we increased the
challenge dose of virus . In Fig . 3,11 and B' (Exp . 2), animals (10 per group) wereWATARI ET AL .
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TABLE I
Crossreactive Protection with Acylated 1-23 Peptide-liposomes
* 8-wk-old BALB/c mice were immunizedonce intrafootpad 3 mo before
HSV challenge. Animals were then challenged with 1 .6 X 106 PFU of
HSV-2and followed for 30 d after challenge . 10 mice were used in each
group .
challenged with a 2.2 X 106 PFU dose of HSV-2 (7-LD5o), 2.5 mo after immu-
nization . In this case, 100% of the control animals (CFA alone) died by day 20 .
80% of the animals receiving acylated peptide-liposome in CFA, however,
remained healthy .
A third experiment was carried out (Fig . 3,C and C'), in which mice (six per
group) were challenged with a 3 .1 X 106 PFU dose of HSV-2 (10-LD5o), 7 mo
after priming . The mice that had been immunized with CFA or acylated 1-23(2)
peptide without liposomes but in CFA were diseased by day 8 after virus
challenge, with the acylated peptide-primed group dying most rapidly and the
CFA control group dying by day 18 . In contrast, 70% of the animals immunized
with acylated peptide-liposomes in CFA showed no HSV-specific symptoms by
day 20 . By day 40, mice immunized with either UV-irradiated HSV-1 or acylated
peptide-liposome had survived the challenge in equal numbers (30%) . Thus,
acylated peptide-liposome in CFA appeared approximately as effective as UV-
inactivated HSV-1 under the conditions of this study .
The difference in the two ways the data is expressed, the percentage ofmice
without symptoms (interpreted as the first appearance of the disease) and per-
centage ofmice surviving (interpreted as the endpoint of the disease or death) is
seen as the displacement of curves to the right by ^-6-10 d, which is the time the
animals are sick but have not died .
We also examined whether the acylated 1-23(1) peptide liposome with the gD
sequence of HSV-1 would protect mice against an HSV-2 challenge . As seen in
Table I, animals immunized with 1-23(1) peptide liposomes 3 mo before HSV-
2 challenge were protected, and furthermore, the 1-23(1) peptide liposome was
comparable to the 1-23(2) peptide liposome in inducing protection .
It has been reported that, in mice, passive administration ofanti-HSV VNA at
the time of HSV challenge can protect mice from a lethal infection (19-22) .
Because this was a possible explanation for the protection seen here, we checked
the sera of mice that had been immunized 7 mo previously (from Exp . 3, Fig .
3,C and C'), 9 d after HSV-2 challenge to determine the VNA titer . As shown
in Table II, neutralizing antibody titers are consistent with the protection in the
HSV-1-primed group but could not explain the protection seen with the acylated
peptide-liposome-primed group .
We examined the animals at later times after virus challenge to determine any
evidence of antigen priming for antibody . As seen in Table 111, mice immunized
Immunized animals* Mice surviving
(day 30)
CFA control 30
Acylated 1-23(1) liposome in CFA 100
Acylated 1-23(2) liposome in CFA 100464 PEPTIDE-SPECIFIC T CELLS PROTECT FROM HERPES SIMPLEX VIRUS
BALB/c mice were challenged with HSV-2 in the footpads 7 mo after a
single immunization of antigen in CFA. Bleedings were done 9 d after
challenge with HSV-2 . The peptide was the 1-23(2) sequence . See also
Exp . 3, Fig. 4C .
TABLE II
Anti-HSV Antibody
Pooled serum from each group
TABLE III
Neutralization titers for :
HSV-1 HSV-2
Kinetics ofAntibody Production in ImmunizedMice
* See Materials and Methods for determination of virus neutralizing titer .
Sera from wk 2 after infection was examined for isotypes of anti-HSV
antibody . In a binding assay with HSV-1- and HSV-2-infected cells,
antibody was determined to be IgM-positive, IgG (y,, Ysa, Ysc, Ys)-
negative, whereas an anti-HSV secondary response serum control was
found to be IgM- and IgG-positive .
¢ All control animals had died .
2.5 mo previously (from Exp . 2, Fig. 3,B and B') were bled before and after
virus challenge to look for an anti-HSV antibody response . It was clear that at 2
wk, there was no difference in the antibody titer between the CFA controls and
the antigen-primed mice . By the third week, the controls had died and the
already low antibody titer in the antigen-primed group fell . Furthermore, the
antibody produced reflected a primary response to the virus, because only IgM
was detected, supporting the conclusion that antibody is not important in
protection induced with the acylated peptide-liposome.
We next considered the T cell response, though as something other than help
for virus-specific antibody, and its correlation with protection from HSV. In
vitro antigen-specific T cell proliferation was determined 2 wk after animals
were immunized . As seen in Table IV, T cells from mice primed to various
forms of peptide, whether protective or not, responded to peptide, gD, and to
virus .
The lack of antibody suggested a role forT cells in protection, but we could
not show a unique T cell function in these protected mice . It was important,
however, to show that even with a proliferative T cell response in all groups,
evidence for T cell protection was present . Thus, we examined both the serum
and lymphocytes from animalsprimed to the acylated 1-23(2)peptide-liposomms
by adoptive transfer into normal mice and then challenge with HSV-2 . It is clear
Week
Anti-HSV-1
CFA-primed
Anti-HSV-2
Acylated
Anti-HSV-1
peptide-lipo-
some-primed
Anti-HSV-2
-2 <2 <2* <2 <2
2 32 64$ 32 32$
3 - - 1 16 8
CFA control 12 6
UV-irradiated HSV-1 in CFA 389 97
Acylated peptide inCFA 6 8
Acylated peptide-liposome in CFA 5 5WATARI ET AL .
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Activation ofTCells by Peptide and Viral Antigens
Discussion
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* ELISA assay titers are reciprocal dilutions. OD considered positive if >0.2 when OD (infected cell
minus control cell)wasread at 405 nm .
$ Infected cell lysates .
4The peptide is the 1-23(2) sequence .
from Table V, Exp . I that animals injected with T cells from acylated peptide
liposome immunized mice were protected, while animals injected with serum
from such mice were completely unprotected . Furthermore, thisT cell protection
was abolished with anti-Lyt-2 treatment (Table V, Exp . 2) .
We have shown that a synthetic acylated peptide corresponding to either an
HSV-I or HSV-2 glycoprotein D (gD) sequence and incorporated into liposomes
induces striking protection from a lethal HSV-2 infection . It is significant that
this synthetic antigen construct is approximately as potent and effective an
immunogen as is UV-inactivated HSV-I under the conditions of this study . Both
give long-term protection (at least 7 mo) with only a single dose of antigen . It is
important to note that the mixture of three components, acylated peptide,
liposome, and an adjuvant is essential for a protective response .
Though acylated peptide-liposome and virus appear similar in their ability to
confer protection, they are clearly different in their effecton the immune system .
Thus, before virus challenge, no virus-specific antibody is detectable in the
Priming antigen Antigen in culture
['H]Thymi-
dine incor-
poration
(cpm x 10-')
Antibody titer*
1-23(2) in CFA (nonprotective) 1-23(2), 50,ug/ml 16 .1 <100
UV HSV-It 9.2
UV HSV-2# 13.2
gD-1, 1 ug/ml 11 .0
OVA, 50 ug/ml -5.3
Acylated peptide¢ in CFA (nonprotective) 1-23(2) 41 .4 <100
UV HSV-1 69.6
UV HSV-2 54.8
gD 64.8
OVA -4.5
Acylated peptide-liposome¢ in CFA (pro- 1-23(2) 50.8 <100
tective) UV HSV-1 20.9
UV HSV-2 14.9
gD 18.6
OVA -1 .1
UV-irradiated HSV-1 in CFA (protective) 1-23(2) 3.8 >3,200
UV HSV-1 64.2
UV HSV-2 31 .8
gD 25.8
OVA 0.3466 PEPTIDE-SPECIFIC T CELLS PROTECT FROM HERPES SIMPLEX VIRUS
TABLE V
Adoptive Transferfrom Animals Immunized with
Acylated Peptide-liposomes
* Cells from mice injected with CFA alone or antigen plus CFA 1 mo
previously were injected into 8-wk-old BALB/c recipients (five mice per
group) intravenously . 24 h later, recipients were challenged with a 7-
LD5o dose (7 .5 x 10 6 PFU, lot 2) of HSV-2 .
$ BALB/c mice (7-wk-old) were injected with acylated 1-23(2) peptide-
liposome inCFAintrafootpad . 1 mo later, spleen andlymphnodeswere
removed and theT cells were prepared . Sera from these animals were
collected at the same time and shown to have no binding or neutraliza-
tion activity for HSV-1 or HSV-2.
6 Sera were collected from animals injected with HSV-2 and used at a
binding titer for HSV-2 of 1 :64 .
w Cells from primed mice were injected into 8-wk-old BALB/c recipients
(10mice pergroup) intravenously . 24 h later, recipients were challenged
with a 7-LD5o dose (2 .1 x 10 6 PFU, lot 6) of HSV-2 .
acylated peptide-liposome-primed group, but it is present in the virus-primed
group. After HSV-2 challenge, the peptide-immune group, like theunimmunized
controls, responds with only a weak primary antibody response to virus, seen
after 2 wk, while the virus-primed group gives a strong secondary response
within a week . Upon adoptive transfer of sera from peptide-primed animals, no
protection was seen, although sera from HSV-primed animals were completely
protective . We conclude that antibody is unlikely to play a significant role in
protection with the acylated peptide-liposome, though we cannot eliminate the
possibility that undetected antibody is responsible (23) .
T cells, however, do seem to be important . Adoptive transfer ofT cells from
either spleen or lymph node of acylated peptide-liposome-primed mice confers
protection to normal mice and this protection is eliminated by pretreatment of
the T cells with anti-Lyt-2 antibody plus complement . An obvious candidate for
this protection is the cytotoxic T cell, which has been shown previously to be
induced in vitro by an antigen construct of viral antigens incorporated into
liposomes (24-28). However, there is evidence against this type of effector cell,
because gD does not induce an Lyt-2+ class I-restricted CTL response (J .
Bennick, personal communication) . Furthermore, the induction of a CTL re-
Exp. Donors Cell or serum
dose
Mice surviv-
ing (day 30)
1 CFA-primed splenic T cells* 4 x 10' 0
Peptide-primed spleen cells* 8 x 10' 100
Peptide-primed splenicT cells* 4 x 10' 100
Peptide-primed LN T cells$ 3.4 x 10' 60
Peptide-primed serum$ 0.2 ml 0
HSV-primed serum¢ 0.2 ml 100
2 CFA-primed splenic T cellsu 4 x 10' 10
Peptide-primed splenicT cells* 4 x 10' 70
Peptide-primed splenic T cells 4 x 10' 0
treated with anti-Lyt 2 + C'
Peptide-primedLN T cells 4x 10' 80WATARI ET AL .
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sponse does not easily explain the results in which animals receiving certain
forms of the peptide (Fig . 3A) do worse than the controls .
On the other hand, the involvement of suppressor T cells in protection might
be suggested from the data presented in Fig. 3A, where animals immunized with
acylated peptide-liposome in saline did worse than animals immunized with
saline alone . One possible mechanism for this effect is that proliferatingT cells
that are harmful (29, 30) are induced in all the immunized groups, but are
checked only in the protected group, which can generate a suppressor T cell
population. The lack of suppressors leads to no protection or enhanced viral
pathogenicity . This explanation is not so unusual when one considers the pa-
thology induced in an autoimmune disease such as experimental allergic enceph-
alomyelitis (EAE). In this case, proliferating class 11-restrictedT cells can induce
the disease, and the suppression of these cells results in refractoriness to EAE
and lack of disease (31) .
In light of the Lyt-2 (suppressor/cytotoxic T cell) nature of protection, it is
not surprising that there is no correlation with the ability ofT cells to proliferate
specifically (a helperT cell function) to the 1-23(2) peptide, gD, or HSV-1 cell
lysates (Table IV) in vitro . That is, T cell proliferation in vitro is not a criterion
for a protective response even when the protection can be shown to be conferred
byT cells .
It is interesting that T cells could be primed with acylated peptide-liposome
in vivo and respond to virus in the absence of a detectable B cell response . The
same 1-23 peptide hasbeen shown to induce anti-HSV antibody responses when
attached to keyhole limpet hemocyanin (KLH), and also to induce short-term
protection (32) . However, in our case, after acylated peptide-liposome priming
and then challenge with HSV-2, the antibody response induced was IgM not
IgG ; a primary response . Whether the T cells provide help for such a primary
antivirus response is difficult to assess ; these T cells might be responding to
antigen only in association with certain antigen-presenting cells such as macro-
phages or dendritic cells, but not others, such as B cells, yielding no antibody
response (33-35) .
The phenomenon of a T cell response with no antibody has been previously
described (9, 10) for a protein antigen that was covalently coupled to a lipid . In
this case, the appearance of delayed-type hypersensitivity (DTH) without anti-
body was attributed to localization of antigen in a T cell region of the lymph
node .
Whatever the mechanism, it is interesting to note that the way antigen is
presented to the animal and its immune system has drastic effectson the outcome
of immunization, either positive or negative . Thus, peptides in this system do
not always confer protection and in some cases seem to enhance viral pathoge-
nicity .
Summary
Immunization against viral pathogens is generally directed toward the induc-
tion of virus neutralizing antibody (VNA) and the maintenance of the potential
for a second-set (IgG) response . Indeed, an elevated level of specific antibody is
considered a reliable clinical indicator that a state ofimmunity exists in the host .468 PEPTIDE-SPECIFIC T CELLS PROTECT FROM HERPES SIMPLEX VIRUS
However, in the case of herpes simplex virus (HSV), the presence of circulating
VNA does not necessarily correlate with protection . Thus, it has been found that
secondary infections occur in individuals even with high neutralizing titers to
HSV, suggesting that antibody to the virus may be useless or even deleterious .
In consideration of these facts, we were interested in inducing a T cell response
to HSV. We had already shown that synthetic peptides corresponding to the
NH3-terminal region of the glycoprotein D (gD) molecule of HSV could induce
a strong T cell response when injected into mice, but did not, by themselves,
confer protection . In this report, we examined the ability of peptides, covalently
coupled to palmitic acid and incorporated into liposomes, to induce virus-specific
T cell responses that confer protection against a lethal challenge of HSV-2 . We
have demonstrated that long-term protective immunity is achieved with a single
immunization in the absence of neutralizing antibody when antigen is presented
in this form . Furthermore, T cells but not serum from such immune mice can
adoptively transfer this protection .
We thankSharon Valentine for excellent technical assistance and C . Hackett, R. Schwartz,
andJ . Yewdell for critically reading some form of this manuscript .
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